Rallybio Corporation Common Stock
RLYBStock
$15.96+387.31%52W
Market Cap$84.59M
P/E—
Div yield—
Beta-0.82
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)172.53%
Price vs S&P 500 (4W)0.85%
VGM Score56.34
Market Capitalization$84.59M
Earnings Surprise History
Q1 26-1.46est. -1.22
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
3.80
2.29
2.17
2.17
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RLYBRallybio Corporation Common Stock | D | C | A | $15.96 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Rallybio is a clinical-stage biotechnology company developing therapeutic candidates for severe, rare diseases driven by complement dysregulation and blood disorders. Its lead program, RLYB116, is a C5 inhibitor targeting immune platelet transfusion refractoriness and refractory antiphospholipid syndrome. The company's pipeline also includes RLYB332, a long-acting antibody in preclinical development for iron overload disorders.